A clinical study for observation of the improvement of vascular endothelial function by Allisartan Isoproxil

A clinical study for Allisartan Isoproxil improving vascular endothelial function

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1900026297

Enrollment

Unknown

Registered

2019-09-29

Start date

2019-10-01

Completion date

Unknown

Last updated

2019-09-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension

Interventions

Control group:Other drug intervention

Experimental group:alisartan ester 240mg treatment

Eligibility

Sex/Gender

All

Age

30 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Selected patients with mild and moderate hypertension aged 30-75 years in the hypertension clinic of our hospital. Hypertension was diagnosed according to the 2010 Chinese guidelines on hypertension: systolic blood pressure >=140mm Hg or diastolic blood pressure >=90mm Hg; 2. Patients signed the informed consent

Exclusion criteria

Exclusion criteria: 1. Blood pressure >=180/110mmhg at baseline; 2. Secondary hypertension; 3. Ejection fraction < 40% of heart failure patients; 4. Acute coronary syndrome, cardiac revascularization; 5. Acute cerebrovascular disease; 6. Severe renal insufficiency (serum creatinine greater than 200 mol/L); 7. Valvular heart disease; 8. Chronic atrial fibrillation; 9. Patients should not take other statins, betts, nitrates, other calcium channel blockers, immunosuppressants, or any other drug that may interfere with the study during the study period.

Design outcomes

Primary

Measure	Time frame
Vascular endothelial function;	—

Countries

China

Contacts

Public ContactYinong Jiang

The First Affiliated Hospital of Dalian Medical University

songwei24@163.com+86 13332297168

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026